These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27938736)

  • 1. FDA Encourages Reporting of Tobacco Product Adverse Experiences.
    Retzky SS
    Chest; 2016 Dec; 150(6):1169-1170. PubMed ID: 27938736
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA Sentinel Initiative - An Evolving National Resource.
    Platt R; Brown JS; Robb M; McClellan M; Ball R; Nguyen MD; Sherman RE
    N Engl J Med; 2018 Nov; 379(22):2091-2093. PubMed ID: 30485777
    [No Abstract]   [Full Text] [Related]  

  • 3. 'Extreme duplication' in the US FDA Adverse Events Reporting System database.
    Hauben M; Reich L; DeMicco J; Kim K
    Drug Saf; 2007; 30(6):551-4. PubMed ID: 17536881
    [No Abstract]   [Full Text] [Related]  

  • 4. New FDA initiatives.
    Somberg JC
    J Clin Pharmacol; 1993 Jul; 33(7):587. PubMed ID: 8366185
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

  • 6. Tobacco companies are evading FDA ban on "light" cigarette labeling, finds study.
    Mayor S
    BMJ; 2013 Mar; 346():f1806. PubMed ID: 23512764
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety concerns at the FDA.
    Lancet; 2005 Feb 26-Mar 4; 365(9461):727-8. PubMed ID: 15733696
    [No Abstract]   [Full Text] [Related]  

  • 8. Nutravigilance: principles and practices to enhance adverse event reporting in the dietary supplement and natural products industry.
    Schmitz SM; Lopez HL; MacKay D
    Int J Food Sci Nutr; 2014 Mar; 65(2):129-34. PubMed ID: 24112316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reporting Adverse Drug Events.
    Feagins LA; Abdelsayed GG; Schairer J;
    Am J Gastroenterol; 2019 Sep; 114(9):1411-1413. PubMed ID: 31464745
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse drug reactions.
    Roswell R; Van Diepen LR; Jones JK; Hicks WE
    Lancet; 2001 Feb; 357(9255):561-2. PubMed ID: 11229704
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing drug safety and consequences of drug withdrawals.
    Mamdani M
    J Am Pharm Assoc (2003); 2004; 44(6):659-60. PubMed ID: 15637847
    [No Abstract]   [Full Text] [Related]  

  • 12. Monitoring and managing adverse drug reactions.
    Fincham JE
    Am Pharm; 1992 Feb; NS32(2):74-81. PubMed ID: 1546634
    [No Abstract]   [Full Text] [Related]  

  • 13. The importance of physicians identifying and reporting adverse drug events.
    Gatti JC
    Am Fam Physician; 2012 Feb; 85(4):318. PubMed ID: 22335311
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA begins active monitoring of drug safety.
    Roehr B
    BMJ; 2008 May; 336(7655):1211. PubMed ID: 18511787
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequential surveillance for drug safety in a regulatory environment.
    Martin D; Gagne JJ; Gruber S; Izem R; Nelson JC; Nguyen MD; Ouellet-Hellstrom R; Schneeweiss S; Toh S; Walker AM
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):707-712. PubMed ID: 29504168
    [No Abstract]   [Full Text] [Related]  

  • 16. Documenting an adverse drug reaction.
    Smith LS
    Nursing; 2005 Oct; 35(10):22. PubMed ID: 16205246
    [No Abstract]   [Full Text] [Related]  

  • 17. IOM panel mulls over adverse-event reporting.
    Young D
    Am J Health Syst Pharm; 2005 Dec; 62(24):2590-1. PubMed ID: 16333055
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).
    Egeberg A; Thyssen JP
    Br J Dermatol; 2023 May; 188(6):793-794. PubMed ID: 36797979
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug Manufacturers' Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration.
    Ma P; Marinovic I; Karaca-Mandic P
    JAMA Intern Med; 2015 Sep; 175(9):1565-6. PubMed ID: 26214395
    [No Abstract]   [Full Text] [Related]  

  • 20. The credibility of the FDA.
    Blankfield RP
    Eur J Prev Cardiol; 2013 Dec; 20(6):992-4. PubMed ID: 23867140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.